Duke Study Challenges Mesothelioma Chemotherapy Practices
Neoadjuvant chemotherapy — often used before aggressive surgery — has shown no definitive survival benefit for patients with pleural mesothelioma cancer, according to a recent study at the Duke University Medical Center.
The study strengthened the growing belief among mesothelioma specialists that the combination of chemotherapy drugs cisplatin and pemetrexed might be a more effective treatment after surgery than before.
“I think the study provides a little more evidence to support what those of us were seeing, that
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Fran Mannino Source Type: news
More News: Alimta | Asbestosis | Cancer | Cancer & Oncology | Chemotherapy | Environmental Health | Mesothelioma | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Study